The lipid nanoparticles market growth is driven by rising demand for advanced drug delivery systems, increasing adoption of mRNA-based therapeutics and vaccines, and continuous innovations in nanomedicine. In addition, expanding pharmaceutical and biotechnology research, growth of gene therapy and oncology pipelines, and rising investment in scalable manufacturing technologies are strengthening market demand. Supportive regulatory frameworks, growing focus on personalized medicine, and collaborations between biotech firms and CDMOs further contribute to the overall expansion of the lipid nanoparticles market.

WILMINGTON, Del., March 5, 2026 /PRNewswire/ -- Allied Market Research published a report, titled, "Lipid Nanoparticles Market by Type (Solid Lipid Nanoparticles, Nanostructured Lipid Carriers and Others), Application (Therapeutics and Research), and End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the lipid nanoparticles market was valued at $0.9 billion in 2023, and is estimated to reach $3.1 billion by 2033, growing at a CAGR of 13.1% from 2024 to 2033.

Request Sample of the Report on Lipid Nanoparticles Market Forecast 2033 -

https://www.alliedmarketresearch.com/request-sample/A323703 

The rising prevalence of chronic diseases, increasing demand for targeted therapeutics, and growing adoption of mRNA-based vaccines have significantly boosted demand for lipid nanoparticle (LNP) technologies in drug delivery, gene therapy, and oncology applications. Advancements in lipid chemistry, microfluidics, and automated encapsulation systems have attracted pharmaceutical and biotechnology companies seeking precise, scalable, and efficient delivery solutions. The expansion of contract development and manufacturing organizations (CDMOs) and integrated digital platforms has further supported market growth by improving formulation consistency, quality control, and process monitoring. In addition, supportive regulatory guidance, increasing investment in LNP-focused research, and collaborations between biotech firms and academic institutions have enhanced product innovation, clinical translation, and therapeutic efficacy, driving the overall expansion of the lipid nanoparticles market.

Report coverage & details   

By type, the solid lipid nanoparticles segment held the highest market share in 2023

The solid lipid nanoparticles segment dominated the lipid nanoparticles market in 2023, driven by their stability, biocompatibility, and ability to encapsulate a wide range of therapeutic molecules. Growing adoption in mRNA vaccines, gene therapies, and oncology therapeutics has significantly boosted demand for solid lipid nanoparticles. Advances in lipid formulation, microfluidics, and scalable manufacturing technologies have enhanced encapsulation efficiency, particle uniformity, and targeted delivery. Additionally, increasing preference for controlled-release and precision therapeutics has further accelerated the adoption of solid lipid nanoparticles globally.

By application, the therapeutics segment held the highest market share in 2023

The therapeutics segment led the market due to rising demand for mRNA-based vaccines, gene therapies, and targeted drug delivery systems. Pharmaceutical and biotechnology companies increasingly use lipid nanoparticles to improve bioavailability, reduce systemic toxicity, and achieve efficient intracellular delivery. The expansion of personalized medicine, oncology pipelines, and infectious disease therapeutics has further driven growth. Continuous innovations in formulation techniques, AI-assisted optimization, and advanced delivery platforms have strengthened the therapeutics segment's dominance.

Want to Explore More, Connect to our Analyst -

https://www.alliedmarketresearch.com/connect-to-analyst/A323703 

By end user, the pharmaceutical & biotechnology companies segment held the highest market share in 2023

Pharmaceutical and biotechnology companies accounted for the largest share in 2023, supported by the increasing development and commercialization of LNP-based therapeutics. These organizations rely on lipid nanoparticles for clinical trials, large-scale manufacturing, and regulatory-compliant product development. Collaboration with contract development and manufacturing organizations (CDMOs) and research institutes has further enhanced product scalability and quality. Additionally, growing R&D investment, pipeline expansion, and focus on innovative drug delivery solutions have contributed to the dominance of this end-user segment.

By region, North America held the highest market share in 2023

North America generated the highest revenue share in 2023, supported by a strong pharmaceutical and biotechnology industry, advanced healthcare infrastructure, and significant investment in nanomedicine research. Early adoption of mRNA therapeutics, regulatory support for innovative drug delivery systems, and collaboration between biotech firms and research institutions further strengthened regional growth. Europe and Asia-Pacific are witnessing steady expansion due to increasing biopharmaceutical R&D and growing adoption of precision medicine, while LAMEA presents emerging growth opportunities with rising healthcare investments and expanding pharmaceutical manufacturing capabilities.

Which key end-user groups are accelerating adoption in the lipid nanoparticles market?

Pharmaceutical and biotechnology companies represent the dominant end-user segment in the lipid nanoparticles market. These organizations extensively use LNPs for mRNA vaccines, gene therapies, and targeted drug delivery, leveraging their precision, stability, and controlled-release capabilities. Academic and research institutes are also key contributors, adopting LNPs for preclinical studies, formulation optimization, and mechanistic research. Contract development and manufacturing organizations (CDMOs) support large-scale production, ensuring consistency, regulatory compliance, and scalability. The combined focus on innovation, pipeline expansion, and efficient clinical translation is driving widespread adoption of lipid nanoparticle technologies across the global healthcare and biopharmaceutical landscape.

For Purchase Related Queries/Enquiry -

https://www.alliedmarketresearch.com/purchase-enquiry/A323703 

Key Players

• ABP Biosciences, LLC. 
• Merck KGaA 
• Cytiva 
• CD Bioparticles 
• CordenPharma 
• Precigenome LLC. 
• Beam Therapeutics 
• Acuitas Therapeutics 
• GENEVANT SCIENCES CORPORATION 
• Helix Biotech, Inc. 

The report provides a detailed analysis of these key players in the global lipid nanoparticles market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.   

Recent developments in the global lipid nanoparticles market

• In January 2021, Sarepta Therapeutics, Inc. and Genevant Sciences, a leading nucleic acid delivery company with a robust and extensive lipid nanoparticle (LNP) patent portfolio, announced a research collaboration and option agreement. The partnership focuses on the delivery of LNP-based gene editing therapeutics within Sarepta's neuromuscular disease pipeline.
• In February 2022, Sarepta Therapeutics, Inc. partnered with GenEdit, Inc., a developer of genetic medicines utilizing its NanoGalaxy™ polymer nanoparticle platform for tissue-selective delivery. The collaboration leverages GenEdit's NanoGalaxy platform and Sarepta's gene editing technology to develop targeted therapeutics for neuromuscular disorders.
• Also in February 2022, Merck completed the acquisition of Exelead for approximately $780 million in cash, following regulatory approvals and customary closing conditions. Exelead, a biopharmaceutical CDMO, specializes in PEGylated products and complex injectable formulations, including LNP-based drug delivery technologies, which are essential for mRNA vaccines, COVID-19 therapeutics, and other indications.

Explore AMR's Extensive Ongoing Coverage on Life Science Industry:

Remote Patient Monitoring Market: Global Opportunity Analysis and Industry Forecast, 2021-2031

Antacids Market: Global Opportunity Analysis and Industry Forecast, 2021-2032

In Vitro Diagnostics Market: Global Opportunity Analysis and Industry Forecast, 2021-2032

Digital Health Market: Global Opportunity Analysis and Industry Forecast, 2021-2030

Gene Synthesis Market: Global Opportunity Analysis and Industry Forecast, 2021-2031

Liquid Biopsy Market: Global Opportunity Analysis and Industry Forecast, 2021-2028

Fluoroscopy Equipment Market: Global Opportunity Analysis and Industry Forecast, 2021-2028

AVENUE - A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:

AMR introduces its online premium subscription-based library on Avenue, designed specifically to offer cost-effective, one-stop solutions for enterprises, investors, and universities. With Avenue, subscribers can avail themselves of an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

About Us

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides end-to-end solutions along with information, education, advocacy, and networking resources to SMEs and early-stage start-ups to bring excellence to their processes. In addition, we offer a nurturing environment required to develop and grow businesses, including business planning; virtual support; market intelligence; acquiring resources; and getting direct access to finance, suppliers, and other experts to boost the growth of businesses and entrepreneurs.

Our bundled and hassle-free business support systems are customized to meet the needs of SME consultants and industry leaders. Moreover, our large network of skilled consultants and experts help start-ups get the business on a roll.

To find out more, visit www.Alliedmarketresearch.com or follow us on Twitter, LinkedIn and Facebook.

Contact

David Correa

1209 Orange Street,

Corporation Trust Center,

Wilmington, New Castle,

Delaware 19801 USA.

Toll Free: +1-800-792-5285

Int'l: +1-503-894-6022

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1-855-550-5975

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lipid-nanoparticles-market-to-reach-3-1-billion-globally-by-2033-at-13-1-cagr-allied-market-research-302705262.html

Die Weltgesundheitsorganisation (WHO) warnt vor einer sich zuspitzenden Gesundheitskrise im Iran und im Libanon infolge des seit Ende Februar andauernden Kriegs im Nahen und Mittleren Osten. Nach WHO-Angaben wurden im Iran seit Beginn der Kampfhandlungen am 28. Februar 18 Angriffe auf Gesundheitseinrichtungen dokumentiert. Dabei seien acht Beschäftigte des Gesundheitswesens getötet worden. Solche Angriffe kosteten nicht nur Leben, sondern entzogen Gemeinden in einer Ausnahmesituation den Zugang zu medizinischer Versorgung, betonte die Organisation. Personal, Patienten und Einrichtungen müssten nach humanitärem Völkerrecht jederzeit geschützt werden.

Auch der Libanon ist laut WHO erheblich betroffen. Im selben Zeitraum wurden dort 25 Angriffe auf Gesundheitszentren registriert, bei denen 16 Menschen ums Leben kamen und 29 verletzt wurden. Parallel dazu berichtet die WHO unter Verweis auf nationale Behörden von hohen Opferzahlen in beiden Ländern. Im Iran seien 1.255 Menschen getötet und mehr als 15.100 verletzt worden. Im Libanon meldeten die Behörden 634 Todesopfer und über 1.586 Verletzte; nach jüngsten Angaben libanesischer Stellen liege die Zahl der Toten bereits bei rund 690. Die WHO spricht von mehr als 800.000 Binnenvertriebenen im Libanon.

Die militärische Eskalation hat massive Fluchtbewegungen ausgelöst. Schätzungen zufolge sind im Iran mehr als 100.000 Menschen innerhalb des Landes vertrieben worden, im Libanon bis zu 700.000. Viele suchten in überfüllten Gebäuden Zuflucht, häufig mit nur eingeschränktem Zugang zu sauberem Wasser und sanitären Einrichtungen. Diese Bedingungen erhöhten das Risiko für Atemwegs- und Durchfallerkrankungen, warnt die WHO. Besonders gefährdet seien Frauen und Kinder, die in Notunterkünften oft nur eingeschränkten Zugang zu medizinischer Versorgung und Vorsorgemaßnahmen hätten.

Zusätzlich zu den direkten Kriegsfolgen beobachtet die WHO im Iran auch Gesundheitsrisiken durch Umwelteinflüsse. Nach Angriffen auf Ölanlagen sei dort sogenannter „schwarzer Regen“ niedergegangen, zudem seien giftige Verbindungen in der Luft gemessen worden. Diese könnten Atemwegsprobleme auslösen, erklärte die Organisation und schloss sich den Empfehlungen iranischer Behörden an, die Bevölkerung vor den gesundheitlichen Gefahren zu warnen. Vor dem Hintergrund anhaltender Luftschläge der USA und Israels auf Ziele im Iran sowie fortgesetzter Angriffe im Libanon weist die WHO darauf hin, dass der Schutz medizinischer Infrastruktur und des Gesundheitspersonals entscheidend sei, um eine weitere Verschärfung der humanitären Lage zu verhindern.